Fortress Biotech (FBIO) EPS (Diluted) Growth (1y) (2019 - 2026)
Analysis
Fortress Biotech (FBIO) EPS (Diluted) Growth (1y) (2019 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.52 Bn | 133.66 Bn | 2.84 Bn | 8.02% |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.69 Bn | 3.93 Bn | -4.52% |
| 3 | Argenx Se | 64.63 Bn | 59.45 Bn | 1.37 Bn | 89.89% |
| 4 | Moderna | 59.30 Bn | 54.16 Bn | 52.00 Mn | 7.59% |
| 5 | Revolution Medicines | 44.41 Bn | 44.41 Bn | - | - |
| 6 | BeOne Medicines | 40.45 Bn | 35.35 Bn | 1.53 Bn | 144.25% |
| 7 | Alnylam Pharmaceuticals | 35.29 Bn | 31.98 Bn | 992.69 Mn | 315.14% |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | -11.18% |
| 9 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 96.41% |
| 10 | Fortress Biotech | 86.15 Mn | -110.42 Mn | 12.58 Mn | -117.39% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -117.39% |
| Dec 31, 2025 | 52.17% |
| Sep 30, 2025 | 114.54% |
| Jun 30, 2025 | 161.49% |
| Mar 31, 2025 | 53.83% |
| Dec 31, 2024 | 66.63% |
| Sep 30, 2024 | 18.82% |
| Jun 30, 2024 | 80.04% |
| Mar 31, 2024 | 69.96% |
| Dec 31, 2023 | 71.48% |
| Sep 30, 2023 | 77.13% |
| Jun 30, 2023 | 7.61% |
| Mar 31, 2023 | 59.71% |
| Dec 31, 2022 | 61.08% |
| Sep 30, 2022 | 58.87% |
| Jun 30, 2022 | 53.12% |
| Mar 31, 2022 | -45.03% |
| Dec 31, 2021 | -102.54% |
| Sep 30, 2021 | -42.36% |
| Jun 30, 2021 | -26.82% |